Medical and Pharmaceutical Investors flock to psychedelic start-ups Sovereign wealth funds Temasek and Mubadala engage in discussions to finance biotech ventures Zartasha MushtaqFebruary 12, 2024
Health & Wellness Compass Pathways, Hackensack Meridian Health collaborate on psilocybin treatment research Partnership signals a milestone agreement for innovative treatment solutions Zartasha MushtaqJanuary 19, 2024
News American Medical Association approves medical code for psychedelic therapies coverage The code was the result of a partnership between U.K.-based COMPASS Pathways and the Multidisciplinary Association for Psychedelic Studies (MAPS) Natalia Buendia CalvilloMay 3, 2023
News MindMed stock surges on Nasdaq listing approval After its stock jumped 66%, MindMed now rivals Compass Pathways as the world's most valuable psychedelic company Jared GnamApril 23, 2021
Medical and Pharmaceutical Psilocybin treats depression as well as common antidepressant: study The first head-to-head clinical trial pushes the psychedelic compound closer to becoming a licensed medicine Jared GnamApril 15, 2021
Psychedelics 2020’s top 5 advancements in psychedelics With major research, legal reform, and more than 20 firms going public, it was major year for the re-emerging field Jared GnamDecember 30, 2020